AIM8OT, yes I agree broadly with you, but just to flesh out a few things which can make for a big difference to the final outcome, I offer the following:
PD’s 35k - 45k beds was Aust alone
we need to factor in a 80% GP
Overseas marketing costs won’t be cheap - but given the stickiness of the recurring revenue, marketing is really an investment in future revenue.
To stay ahead of the pack, significant money has to be invested in R&D. PCK should look to become the world’s leading analysts of pain & discomfort that creates a reliable standard used by all medical staff for all patient types, not just dementia sufferers.
PainChek General Discussion, page-8557
-
- There are more pages in this discussion • 11,856 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PCK (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.0¢ |
Change
0.004(11.1%) |
Mkt cap ! $65.43M | |||
| Open | High | Low | Value | Volume |
| 3.6¢ | 4.0¢ | 3.5¢ | $58.14K | 1.592M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 606713 | 3.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.0¢ | 1458683 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| PCK (ASX) Chart |